Spruce Biosciences is scheduled to resume trading at 4:40 pm ET, with quotation set to resume at 4:35 pm ET, according to Nasdaq. Shares had been halted as the company disclosed that its CAHmelia-203 study did not meet efficacy endpoint, announced that it is cutting 21% of staff, and reported FY23 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRB:
- SPRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Three new option listings on February 27th
- Spruce Biosciences price target raised to $9 from $8 at RBC Capital
- Guggenheim optimistic ahead of readouts, starts Spruce Biosciences at Buy
- Spruce Biosciences initiated with a Buy at Guggenheim
